Every Form 4 that Soleno Therapeutics, Inc. (SLNO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SLNO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLNO filings page.
Soleno Therapeutics officer Kristen Yen reported disposing of all her company equity in connection with a cash merger. On May 18, 2026, 37,639 shares of Common Stock were surrendered to the issuer, leaving her with zero shares reported after the transaction.
Footnotes explain that, under an Agreement and Plan of Merger among Soleno Therapeutics, Neocrine Biosciences and a merger subsidiary, each share of Common Stock and each vested and unvested RSU was cancelled and converted into the right to receive $53.00 in cash per share. Multiple employee stock options, including grants covering 55,392 shares at an exercise price of $5.25 per share and 11,900 shares at $43.65 per share, were also cancelled in exchange for cash equal to their spread to the $53.00 merger consideration, so no options remain outstanding for Yen.
Soleno Therapeutics director Birgitte Volck reported the cancellation of her equity in connection with Soleno’s merger with Neurocrine Biosciences. She disposed of 17,536 shares of Common Stock to the issuer on May 18, 2026, with each share converted into the right to receive $53.00 in cash as merger consideration.
Previously granted restricted stock units were also cancelled and similarly converted into the cash consideration. Multiple stock option awards, including 10,000 options with a $5.25 exercise price, were cancelled in exchange for cash equal to $53.00 minus the exercise price, multiplied by the options’ share count. Following these transactions, the filing shows Volck with no remaining Soleno shares or options.
Soleno Therapeutics director Andrew Sinclair reported the disposition of his equity in connection with Soleno’s merger with Neocrine Biosciences. On May 18, 2026, 10,491 shares of Common Stock and multiple stock options were canceled as they were transferred back to the issuer.
Under the merger agreement, each share of Common Stock and each vested and unvested RSU was converted into the right to receive $53.00 in cash per share. Each stock option was canceled for a cash payment equal to the $53.00 merger consideration minus its exercise price, multiplied by the number of option shares.
Following these transactions, Sinclair reported holding zero shares of Soleno Common Stock and no remaining stock options in this filing.
Soleno Therapeutics director Matthew Pauls reported a merger-related cash-out of his equity stake. On May 18, 2026, he disposed of 10,491 shares of common stock and no shares remained directly held afterward.
In connection with the merger of Soleno with Sigma Merger Sub, making Soleno a wholly owned subsidiary of Neocrine Biosciences, each share of common stock and each vested and unvested RSU was cancelled and converted into the right to receive $53.00 in cash per share. A stock option covering 9,063 shares with a $4.60 exercise price was cancelled in exchange for a cash payment calculated as the difference between the $53.00 merger consideration and the exercise price, multiplied by the number of option shares.
Soleno Therapeutics’ Chief Business Officer Kevin Norrett reported dispositions tied to the company’s merger with Neocrine Biosciences. He surrendered 17,786 shares represented by previously reported RSUs and two stock option grants covering 4,000 and 64,286 shares of Common Stock.
In the merger, each RSU and each share of Common Stock was cancelled and converted into the right to receive $53.00 in cash per share, while each stock option was cancelled for a cash payment equal to its intrinsic value. Following these transactions, Norrett holds no directly reported Soleno common shares or related stock options in this filing.
Soleno Therapeutics' Chief Commercial Officer, Meredith Manning, reported the cancellation of her equity in connection with Soleno’s merger with Neurocrine Biosciences. On May 18, 2026, all of her 64,507 shares of common stock were disposed of back to the issuer and converted into a cash payment.
Footnotes explain that, under the merger agreement, each share of common stock and each vested or unvested RSU was cancelled and converted into the right to receive $53.00 in cash per share. Several employee stock option grants were also cancelled in exchange for cash equal to the spread between $53.00 and their exercise prices, multiplied by the number of option shares.
After these issuer dispositions, the filing shows no remaining common stock or options for Manning from these reported awards, reflecting the change from equity in Soleno to cash consideration at closing of the merger.
Soleno Therapeutics Chief Development Officer Manher Joshi disposed of his remaining equity in connection with Soleno’s merger into Neurocrine Biosciences. A total of 20,171 shares of common stock represented by restricted stock units were cancelled and converted into the right to receive $53.00 per share in cash. Two stock option grants covering 4,700 shares at $43.65 and 72,321 shares at $46.31 were also cancelled for cash payments based on the $53.00 merger price. Following these transactions, the filing shows no remaining common stock or options held directly by Joshi.
Soleno Therapeutics senior vice president of clinical development Michael F. Huang reported dispositions tied to the company’s cash merger with Neocrine Biosciences. On May 18, 2026, all of his Soleno common shares and equity awards were cancelled and converted into cash.
The filing shows 39,823 shares of common stock disposed to the issuer, leaving him with zero common shares. In addition, stock options covering 11,900, 13,800, and 110,000 shares were cancelled for cash equal to the $53.00 per-share merger consideration minus each option’s exercise price. These are mechanical merger-related cash-outs, not open-market trades.
Soleno Therapeutics insider Patricia C. Hirano reported dispositions of all remaining equity awards in connection with the company’s merger with Neocrine Biosciences, Inc. On May 18, 2026, Soleno became a wholly owned subsidiary of Neocrine via a merger.
Each issued and outstanding share of Soleno common stock, including shares represented by restricted stock units, was cancelled and converted into the right to receive $53.00 in cash per share, described as the Merger Consideration. Hirano disposed of 22,702 common shares to the issuer and now holds no common stock directly.
Multiple derivative awards were also cancelled for cash. Employee stock options and a warrant were exchanged for cash payments based on the difference between the $53.00 Merger Consideration and their respective exercise prices, multiplied by the number of underlying shares. Following these transactions, all reported options and the warrant show zero remaining balance.
Soleno Therapeutics director Mark W. Hahn reported a disposition of 10,046 shares of common stock to the issuer. These shares were represented by previously reported restricted stock units (RSUs).
In connection with the merger of Sigma Merger Sub, Inc. into Soleno Therapeutics, Inc., making Soleno a wholly owned subsidiary of Neocrine Biosciences, Inc., each vested and unvested RSU was cancelled and converted into the right to receive $53.00 in cash per unit as merger consideration. Following this cancellation, Hahn reported holding no shares of Soleno common stock directly.
Soleno Therapeutics' chief financial officer Jennifer Fulk reported merger-related dispositions of equity awards. On May 18, 2026, 39,200 shares of Common Stock represented by restricted stock units were cancelled in connection with Soleno’s merger into a wholly owned subsidiary of Neocrine Biosciences.
Each vested and unvested restricted stock unit was converted into the right to receive $53.00 in cash per share as merger consideration. On the same date, an employee stock option covering 67,660 shares at an exercise price of $39.06 per share was cancelled in exchange for a cash payment based on the difference between the $53.00 merger consideration and the option exercise price. Following these transactions, the filing shows no remaining holdings from these awards.
Soleno Therapeutics director Dawn Carter reported a disposition of 16,991 shares of Common Stock in connection with the company’s acquisition. On May 18, 2026, Sigma Merger Sub, Inc. merged with and into Soleno Therapeutics, Inc., which continued as a wholly owned subsidiary of Neocrine Biosciences, Inc.
In the merger, each issued and outstanding share of Soleno’s Common Stock was cancelled and converted into the right to receive $53.00 in cash, described as the Merger Consideration. Certain shares were represented by previously reported restricted stock units that were also cancelled and converted into the same $53.00 cash right. Following this transaction, Carter reported owning no Soleno shares.
Soleno Therapeutics CEO Anish Bhatnagar reported dispositions of all his company equity in connection with Soleno’s cash merger with Neocrine Biosciences. On May 18, 2026, he disposed of 583,656 shares of Common Stock back to the issuer, consistent with the merger closing.
Footnotes state that each issued and outstanding Soleno Common Share and each vested and unvested restricted stock unit was cancelled and converted into the right to receive $53.00 in cash per share as merger consideration. Multiple employee stock options covering various share amounts and exercise prices were also cancelled at the effective time of the merger in exchange for cash equal to the spread between the $53.00 merger consideration and their respective exercise prices.
Following these issuer dispositions, the filing shows Bhatnagar with zero shares and zero listed options remaining, reflecting the completion of the cash-out of his Soleno holdings as the company became a wholly owned subsidiary of Neocrine Biosciences.
Soleno Therapeutics Chief Commercial Officer Meredith Manning reported open-market sales of a total of 7,522 shares of common stock of SOLENO THERAPEUTICS INC on March 27, 2026. According to the footnotes, these shares were sold to cover tax withholding obligations tied to vesting restricted stock units. After these transactions, Manning directly holds 64,507 shares of common stock.
Soleno Therapeutics senior vice president of clinical development Michael F. Huang reported open-market sales of company common stock primarily to cover tax obligations from vesting restricted stock units. He sold a total of 6,582 shares in multiple trades on March 27, 2026, at weighted average prices around $30–$32 per share. Following these transactions, he continues to hold 39,823 shares of common stock directly.
Soleno Therapeutics chief financial officer Jennifer Fulk reported equity awards tied to her compensation. On March 2, 2026, she acquired options covering 67,660 shares of common stock through an exercise or conversion of a derivative security and was granted 39,200 shares of common stock in the form of restricted stock units.
The RSUs vest in four equal installments of 25% each on March 2, 2027, March 2, 2028, March 2, 2029, and March 2, 2030, contingent on her continued service. The option vests with one-fourth on March 2, 2027, then in equal monthly installments over the following 36 months, also conditioned on continued service.
Soleno Therapeutics reported new equity awards for officer Kristen Yen, its SVP Global Clinical Operations and Patient Advocacy. On January 21, 2026, Yen received 10,400 shares of Common Stock for no cash cost, structured as restricted stock units. These RSUs are scheduled to vest 100% on December 15, 2027, if she continues as a service provider under the company’s 2014 Equity Incentive Plan.
Yen also received an employee stock option covering 11,900 shares of Common Stock at an exercise price of $43.65 per share. This option begins vesting on February 1, 2026, with 1/48th of the shares vesting monthly thereafter, contingent on continued service. After these transactions, she beneficially owned 37,639 shares of Common Stock directly, along with 11,900 stock options.
Soleno Therapeutics executive Kevin Norrett reported new equity awards in the form of restricted stock units and stock options. On January 21, 2026, he received 3,500 restricted stock units of Common Stock at no cost, bringing his beneficial ownership to 17,786 RSUs representing shares of Common Stock. These RSUs are scheduled to vest 100% on December 15, 2027, as long as he continues as a service provider under the company’s 2014 Equity Incentive Plan.
On the same date, he was also granted an employee stock option to purchase 4,000 shares of Common Stock at an exercise price of $43.65 per share. This option vests in equal monthly installments, with 1/48th of the shares vesting on February 1, 2026 and on each monthly anniversary thereafter, subject to his continued service. Both awards are standard compensation arrangements that align his interests with long-term company performance.
Soleno Therapeutics’ Chief Commercial Officer Manning Meredith received new equity awards. On January 21, 2026, Meredith was granted 28,600 shares of Common Stock in the form of restricted stock units at a grant price of $0. These RSUs are scheduled to vest 100% on December 15, 2027, as long as Meredith continues as a service provider under the company’s 2014 Equity Incentive Plan.
On the same date, Meredith was also granted an employee stock option for 32,800 shares of Common Stock with an exercise price of $43.65 per share. One forty‑eighth of these option shares will vest on February 1, 2026, with additional vesting on each monthly anniversary, subject to continued service. After these transactions, Meredith beneficially owned 72,029 shares of Common Stock directly, including RSUs subject to vesting conditions.
Soleno Therapeutics reported that its Chief Financial Officer, James H. Mackaness, received equity awards on January 21, 2026. He was granted 28,600 shares of Common Stock in the form of restricted stock units (RSUs) at a price of $0 per share, bringing his directly held Common Stock to 131,763 shares after the grant. These RSUs are scheduled to vest 100% on December 15, 2027, contingent on his continued service under the company’s 2014 Equity Incentive Plan.
On the same date, he also received an employee stock option for 32,800 shares of Common Stock at an exercise price of $43.65 per share, expiring on January 21, 2036. One forty-eighth of these option shares will vest on February 1, 2026, with additional installments on each monthly anniversary, subject to continued service.
Soleno Therapeutics reported an equity compensation grant to its Chief Development Officer, Joshi Manher. On January 21, 2026, Manher was awarded 4,100 restricted stock units (RSUs) of common stock at a price of $0 per unit, increasing his directly held RSUs tied to common stock to 20,171 following the grant. Each RSU represents the right to receive one share of common stock, and 100% of this new RSU grant is scheduled to vest on December 15, 2027, subject to continued service under the company’s 2014 Equity Incentive Plan.
On the same date, Manher also received an employee stock option covering 4,700 shares of common stock with an exercise price of $43.65 per share. The option vests in equal monthly installments, with 1/48th of the shares vesting on February 1, 2026 and on each one-month anniversary thereafter, conditioned on continued service. All reported holdings in this filing are listed as direct ownership.
Soleno Therapeutics senior vice president of clinical development Michael F. Huang reported equity awards in the company’s stock. On January 21, 2026, he received 10,400 shares of Common Stock for no cash consideration, structured as restricted stock units that each convert into one share if service conditions are met. Following this award, he directly beneficially owned 46,405 shares of Common Stock, some of which are RSUs subject to their own vesting terms.
On the same date, he was also granted an employee stock option covering 11,900 shares of Common Stock at an exercise price of $43.65 per share, expiring on January 21, 2036. One forty‑eighth of the option vests on February 1, 2026 and on each monthly anniversary thereafter, provided he continues as a service provider, while the 10,400 RSUs are scheduled to vest in full on December 15, 2027 under the same continued‑service condition.
Soleno Therapeutics officer Patricia C. Hirano reported new equity awards. On January 21, 2026, she received 10,400 shares of Common Stock in the form of restricted stock units (RSUs), with each RSU representing one future share. These RSUs are scheduled to vest 100% on December 15, 2027, if she continues as a service provider under the company’s equity plan through that date.
On the same day, she was also granted an employee stock option for 11,900 shares of Common Stock at an exercise price of $43.65 per share. One forty-eighth of these option shares start vesting on February 1, 2026 and then monthly thereafter, contingent on continued service, and the option expires on January 21, 2036. After these transactions, she beneficially owned 22,702 shares of Common Stock directly, along with the newly granted option.
Soleno Therapeutics chief executive officer and director Anish Bhatnagar reported new equity awards in the form of restricted stock units and stock options. On January 21, 2026, he received 114,200 shares of Common Stock at $0 cost, identified in the footnotes as restricted stock units (RSUs) that each represent a right to one share of Common Stock. These RSUs are scheduled to vest 100% on December 15, 2027, as long as he continues as a service provider under the company’s 2014 Equity Incentive Plan.
On the same date, Bhatnagar was granted an employee stock option covering 131,400 shares of Common Stock at an exercise price of $43.65 per share. The option begins vesting on February 1, 2026, with 1/48th of the shares vesting on that date and on each monthly anniversary thereafter, subject to continued service. After these transactions, he directly held 583,656 shares of Common Stock and 131,400 derivative securities (stock options).
Soleno Therapeutics insider reports routine tax withholding transaction. A senior officer of Soleno Therapeutics Inc. reported an automatic disposition of company stock related to vested restricted stock units on December 15, 2025.
The filing shows that 904 shares of common stock were withheld by the company at a price of $49.95 per share to cover the officer's tax obligations when RSUs vested. After this transaction, the officer beneficially owned 27,239 shares of Soleno Therapeutics common stock. The reported RSUs each represent a contingent right to receive one share of common stock, subject to vesting conditions.
The reporting person serves as SVP Global Clinical Operations and Patient Advocacy, and this filing reflects a standard administrative equity compensation event rather than an open-market trade.
Soleno Therapeutics insider updates equity holdings after RSU vesting
A Soleno Therapeutics officer, the Chief Commercial Officer, reported an automatic share withholding related to restricted stock units. On December 15, 2025, the company withheld 1,922 shares of common stock at $49.95 per share to cover the reporting person's tax obligations when RSUs vested on that date. After this tax withholding, the officer beneficially owned 43,429 shares of common stock, some of which are RSUs, with each RSU representing a contingent right to receive one share subject to its vesting schedule and conditions.
Soleno Therapeutics Inc. reported an insider equity transaction by its Chief Financial Officer, James Mackaness. On December 15, 2025, 2,013 shares of common stock were disposed of at a price of $49.95 per share. The shares were withheld by the company to cover the officer’s tax obligations arising from the vesting and settlement of restricted stock units (RSUs).
Following this tax withholding transaction, the reporting person beneficially owns 103,163 shares of Soleno Therapeutics common stock. A portion of this balance consists of RSUs, each representing a contingent right to receive one share of common stock, subject to applicable vesting schedules and conditions.
Soleno Therapeutics senior vice president of clinical development reported a routine share withholding transaction related to equity compensation. On December 15, 2025, the officer had 812 shares of common stock withheld by the company at a price of $49.95 per share to cover tax obligations arising from the vesting and settlement of restricted stock units (RSUs). After this tax withholding, the officer beneficially owned 36,005 shares of Soleno Therapeutics common stock. Some of these holdings consist of RSUs, each representing a contingent right to receive one share of common stock, subject to vesting schedules and conditions.
Soleno Therapeutics officer and Senior Vice President of Regulatory Affairs reported an automatic share withholding related to vested restricted stock units (RSUs). On December 15, 2025, 904 shares of common stock were withheld by the company to cover the reporting person’s tax obligations upon RSU settlement at a price of $49.95 per share. After this tax withholding transaction, the insider beneficially owned 12,302 shares of Soleno Therapeutics common stock. Certain of the remaining holdings consist of RSUs, each representing a contingent right to receive one share of common stock, subject to their vesting schedules and conditions.
Soleno Therapeutics chief executive officer and director Anish Bhatnagar reported equity transactions in company stock. On December 15, 2025, 7,620 shares of common stock were withheld by the company at a price of $49.95 to cover tax obligations related to vested restricted stock units. On the same date, he transferred 100,000 shares of common stock as a gift, for no consideration, to two family trusts for the benefit of his descendants.
After these transactions, Bhatnagar beneficially owned 469,456 shares of Soleno Therapeutics common stock, some of which are in the form of restricted stock units, each representing a contingent right to receive one share subject to vesting conditions. He reports beneficial ownership of the gifted shares only to the extent of any pecuniary interest and disclaims beneficial ownership of the shares held by the trusts.
Soleno Therapeutics (SLNO) reported an equity award and option activity for its Chief Business Officer. On 11/17/2025, the officer acquired 14,286 restricted stock units (RSUs) of common stock at a price of $0, all held directly after the transaction. Each RSU represents the right to receive one share of common stock.
One-half of these RSUs will vest on November 17, 2026, with one third of the remaining units vesting on each one-year anniversary after that, as long as the officer continues as a service provider. The filing also shows an employee stock option covering 64,286 shares of common stock at an exercise price of $47.25 per share, expiring on 11/17/2035. One-fourth of the option shares will vest on November 17, 2026, and one forty-eighth of the shares will vest monthly thereafter, subject to continued service.
Soleno Therapeutics (SLNO) disclosed a director equity award. On 10/13/2025, the reporting person was granted 10,046 restricted stock units (RSUs) at $0. Each RSU represents the right to receive one share of common stock.
Vesting: one-third on October 13, 2026 and on each one-year anniversary thereafter, subject to continued service. Beneficial ownership following the grant was 10,046 shares, held directly.